BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan N, Mahmud N, Trivedi C, Reinisch W, Lewis JD. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut 2021;70:1657-64. [PMID: 33753416 DOI: 10.1136/gutjnl-2021-324356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Alrashed F, Alasfour H, Shehab M. Impact of biologics and small molecules for inflammatory bowel disease on COVID ‐19‐related hospitalization and mortality: A systematic review and meta‐analysis. JGH Open. [DOI: 10.1002/jgh3.12728] [Reference Citation Analysis]
2 Hisamatsu T. Management of inflammatory bowel disease during the COVID-19 pandemic. Immunol Med 2021;:1-8. [PMID: 34530694 DOI: 10.1080/25785826.2021.1978205] [Reference Citation Analysis]
3 Mahmud N, Shah Y, Khan N. Prevalence of SARS-COV-2 Vaccination and Factors Impacting Likelihood of Vaccination in a Nationwide Veterans Affairs Cohort of IBD Patients. Inflamm Bowel Dis 2022:izac083. [PMID: 35397005 DOI: 10.1093/ibd/izac083] [Reference Citation Analysis]
4 Alvarado DM, Son J, Thackray LB, Gomez Castro MF, Prasad S, Cui X, Sonnek NM, Diamond MS, Ding S, Ciorba MA. Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice. Inflamm Bowel Dis 2021:izab274. [PMID: 34849936 DOI: 10.1093/ibd/izab274] [Reference Citation Analysis]
5 Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Aliment Pharmacol Ther 2021;54:1432-41. [PMID: 34694009 DOI: 10.1111/apt.16663] [Reference Citation Analysis]
6 Macaluso FS, Giuliano A, Fries W, Viola A, Abbruzzese A, Cappello M, Giuffrida E, Carrozza L, Privitera AC, Magnano A, Ferracane C, Scalisi G, Minissale MG, Giangreco E, Garufi S, Bertolami C, Cucinotta U, Graziano F, Casà A, Renna S, Teresi G, Rizzuto G, Mannino M, Maida M, Orlando A. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19. Inflamm Bowel Dis 2022:izac064. [PMID: 35385102 DOI: 10.1093/ibd/izac064] [Reference Citation Analysis]
7 Koletzko L, Klucker E, Le Thi TG, Breiteneicher S, Rubio-Acero R, Neuhaus L, Stark RG, Standl M, Wieser A, Török H, Koletzko S, Schwerd T. Following Pediatric and Adult IBD Patients through the COVID-19 Pandemic: Changes in Psychosocial Burden and Perception of Infection Risk and Harm over Time. J Clin Med 2021;10:4124. [PMID: 34575235 DOI: 10.3390/jcm10184124] [Reference Citation Analysis]
8 Kjeldsen S, Nielsen J, Mertz Nørgård B, Kjeldsen J. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. Inflamm Bowel Dis 2021:izab299. [PMID: 34849917 DOI: 10.1093/ibd/izab299] [Reference Citation Analysis]
9 Sparks JA, Wallace ZS, Robinson PC. Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. Curr Opin Rheumatol 2021;33:412-8. [PMID: 34171857 DOI: 10.1097/BOR.0000000000000812] [Reference Citation Analysis]
10 Shehab M, Abu-Farha M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Alphonse Thanaraj T, Channanath A, Ali H, Abubaker J, Almulla F. Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study. J Clin Med 2021;10:5362. [PMID: 34830644 DOI: 10.3390/jcm10225362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Khan N, Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology 2021;161:827-36. [PMID: 34048782 DOI: 10.1053/j.gastro.2021.05.044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
12 Khan N, Patel D, Trivedi C, Pernes T, Kavani H, Xie D, Yang YX. The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: a nationwide cohort study of 56 410 IBD patients. Aliment Pharmacol Ther 2022;55:64-72. [PMID: 34664313 DOI: 10.1111/apt.16610] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Pokryszka J, Wagner A, Wiedermann U, Tobudic S, Herkner H, Winkler S, Brehovsky S, Reinisch W, Novacek G. Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines 2022;10:759. [DOI: 10.3390/vaccines10050759] [Reference Citation Analysis]
14 Taylor R 3rd, Mallon D. COVID-19 and Pediatric Gastroenterology. Pediatr Clin North Am 2021;68:1157-69. [PMID: 34736582 DOI: 10.1016/j.pcl.2021.07.003] [Reference Citation Analysis]
15 Alrashed F, Battat R, Abdullah I, Charabaty A, Shehab M. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol 2021;8:e000774. [PMID: 34725056 DOI: 10.1136/bmjgast-2021-000774] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Liu X, Yu Z, Wu Y, Shi S, Yao J, Feng X, Wen D, Shi Z, Zhao Z, Li Y, Zhou H, You C, Lin Y, Yang M. The immune regulatory effects of tetrahedral framework nucleic acid on human T cells via the mitogen-activated protein kinase pathway. Cell Prolif 2021;54:e13084. [PMID: 34170049 DOI: 10.1111/cpr.13084] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Wetwittayakhlang P, Albader F, Golovics PA, Hahn GD, Bessissow T, Bitton A, Afif W, Wild G, Lakatos PL. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2021;2021:7591141. [PMID: 34858891 DOI: 10.1155/2021/7591141] [Reference Citation Analysis]
18 Nørgård BM, Zegers FD, Nielsen J, Kjeldsen J. Post COVID-19 hospitalizations in patients with chronic inflammatory diseases - A nationwide cohort study. J Autoimmun 2021;125:102739. [PMID: 34757259 DOI: 10.1016/j.jaut.2021.102739] [Reference Citation Analysis]
19 Lee JW, Song EM, Jung SA, Jung SH, Kim KW, Koh SJ, Lee HJ, Hong SW, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study. J Korean Med Sci 2021;36:e336. [PMID: 34904410 DOI: 10.3346/jkms.2021.36.e336] [Reference Citation Analysis]